Log in to search using one of your social media accounts:

 

Potential impact of amantadine on aggression in chronic traumatic brain injury - Hammond FM, Malec JF, Zafonte RD, Sherer M, Bogner J, Dikmen S, Whitney MP, Bell KR, Perkins SM, Moser EA.
OBJECTIVE: To assess the effects of amantadine on anger and aggression among individuals with a chronic traumatic brain injury (TBI). METHODS: A cohort of 118 persons with chronic TBI (>6 months postinjury) and moderate-severe aggression selected f... (Source: SafetyLit)
Source: SafetyLit - September 15, 2017 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Gocovri (Amantadine Extended Release Capsules, for Oral Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 13, 2017 Category: Drugs & Pharmacology Source Type: news

Gocovri (Amantadine Extended Release Capsules, for Oral Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 8, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri (amantadine) extended release capsules (previously ADS-5102) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 24, 2017 Category: Drugs & Pharmacology Source Type: news

Apace Packaging LLC Issues Voluntary Nationwide Recall of Cyclobenzaprine HCL and Amantadine HCL (Lot 16710) Due to Potential Mislabeling
Apace Packaging LLC is voluntarily recalling one lot of Cyclobenzaprine HCl Tablet, USP 5 mg 50ct Unit Dose, NDC# 50268-190-15, Lot Number 16710 and one lot of Amantadine HCl Capsule, USP 100 mg 50ct Unit Dose NDC# 50268-069-15, Lot Number 16710 to the Retail level. These products have been recalled due to a potential mislabeling. A small number of cartons containing Cyclobenzaprine HCl Tablets 5 mg UD Blister Cards may potentially be mislabeled as Amantadine HCl Capsules, USP 100 mg. The unit dose blisters inside the carton are correctly labeled as Cyclobenzaprine HCl Tablet, USP 5 mg. (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 27, 2017 Category: Food Science Source Type: news

Stroke patient speaks due to Parkinson's disease drug
An unnamed patient, 36, believed to be from Berlin, who was only being kept alive by medical intervention, was able to speak in short sentences after being given the drug amantadine. (Source: the Mail online | Health)
Source: the Mail online | Health - July 26, 2017 Category: Consumer Health News Source Type: news

Corneal Edema: Is Your Patient Receiving Amantadine? Corneal Edema: Is Your Patient Receiving Amantadine?
Amantadine-induced corneal edema, which can mimic a number of other ocular conditions, is best treated simply by discontinuation of the drug.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 28, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Extended-Release Amantadine Effective for Dyskinesia in PD Extended-Release Amantadine Effective for Dyskinesia in PD
A phase 3 study shows a once-daily formulation of amantadine is superior to placebo in reducing severity and duration of levodopa-induced dyskinesia in patients with Parkinson's.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Lannett Announces Approval For Amantadine Hydrochloride Capsules USP, 100 mg
PHILADELPHIA, June 16, 2017 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Amanta... Biopharmaceuticals, Generics, FDA Lannett, Amantadine, Symmetrel, influenza (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 16, 2017 Category: Pharmaceuticals Source Type: news

New Amantadine Pill Cuts Dyskinesia in Parkinson's (CME/CE)
(MedPage Today) -- But questions about cost-effectiveness remain (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - June 12, 2017 Category: Consumer Health News Source Type: news

Drug reduces dyskinesia, 'off' times in Parkinson's patients
(Reuters Health) - An experimental extended-release version of the drug amantadine can reduce the duration of the involuntary dancing-like movements seen in people whose long-term use of levodopa has kept their Parkinson ’s disease under control. (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

New NIST data to aid production and storage of 'fascinating' medication
(National Institute of Standards and Technology (NIST)) Amantadine hydrochloride may be the most common medication you've never heard of. Now, chemists at the National Institute of Standards and Technology (NIST) and collaborators have published the very first data on this important chemical's thermodynamic properties, including data on how it responds to heat and changes from a solid into a gas. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 2, 2017 Category: Global & Universal Source Type: news

New Amantadine Formulation May Improve Walking in MS New Amantadine Formulation May Improve Walking in MS
Phase 2 results show significant walking speed improvement in patients with MS who received an investigational formulation of amantadine hydrochloride ER and'warrant further development,'say investigators.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 1, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Symmetrel (Amantadine Hydrochloride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 26, 2017 Category: Drugs & Pharmacology Source Type: news

Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
EMERYVILLE, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ADS-5102 (amantadine... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 6, 2017 Category: Drugs & Pharmacology Source Type: news

Acute hallucinosis related to amantadine use in the setting of traumatic brain injury: a case report - Schoen B, Eickmeyer S.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - October 1, 2016 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Adjunctive amantadine treatment for aggressive behavior in children: a series of eight cases - McGrane IR, Loveland JG, Zaluski HJ.
We describe our experience with adjunctive amantadine treatment for... (Source: SafetyLit)
Source: SafetyLit - August 4, 2016 Category: Global & Universal Tags: Age: Infants and Children Source Type: news

Long-Acting Drug Safe in Dyskinesia (CME/CE)
(MedPage Today) -- Extended-release amantadine well tolerated over 41 weeks (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 23, 2016 Category: Geriatrics Source Type: news

Extended-Release Amantadine May Improve Levodopa Dyskinesia Control
VANCOUVER — An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals. (Source: Caring for the Ages)
Source: Caring for the Ages - May 28, 2016 Category: Health Management Authors: M. Alexander Otto Source Type: news

Extended-release amantadine may improve levodopa dyskinesia control
VANCOUVER – An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals. Amantadine... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 21, 2016 Category: Neurology Source Type: news

Extended-release amantadine may improve levodopa dyskinesia control
VANCOUVER – An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals. Amantadine... (Source: Family Practice News)
Source: Family Practice News - April 21, 2016 Category: Primary Care Source Type: news

Amantadine (Symmetrel, Lysovir) may be out of stock due to manufacturing delays
Anyone currently taking amantadine, sometimes prescribed for fatigue in MS, may want to check with their pharmacist to ensure there will be stocks ready for their next prescription. (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - September 28, 2014 Category: Neurology Source Type: news

Adamas starts Phase III trial of ADS-5102 to treat PD patients with levodopa-induced dyskinesia
US-based Adamas Pharmaceuticals has started a pivotal Phase III clinical trial of its most advanced wholly owned product candidate ADS-5102 (amantadine HCl) for the treatment of patients with Parkinson's disease (PD) who have developed movement disor… (Source: Drug Development Technology)
Source: Drug Development Technology - June 10, 2014 Category: Pharmaceuticals Source Type: news

Amantadine Has Lasting Benefit on Levodopa-Induced DyskinesiaAmantadine Has Lasting Benefit on Levodopa-Induced Dyskinesia
A large study shows a 'clinically important' and long-lasting antidyskinetic effect of amantadine in Parkinson's patients receiving levodopa. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 8, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Featured in NEJM Journal Watch: Amantadine for Irritability After Traumatic Brain Injury (FREE)
By the NEJM Journal Watch Editors It's a first-line option, according … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 24, 2013 Category: Primary Care Source Type: news

New Sleep Articles from October
It was another busy month with plenty of new information available about sleep disorders. Review some of the new sleep articles available from October. Discover surprising signs of obstructive sleep apnea and insomnia, as well as indications that your continuous positive airway pressure (CPAP) is not working properly. Expand your vocabulary by learning about three important neurotransmitters: GABA, norepinephrine, and epinephrine. Consider some reasons why you may wish to avoid using sleeping pills altogether. Finally, learn about the use of the prescription medication amantadine to treat fatigue in multiple sclerosis. Re...
Source: About Sleep Disorders - October 30, 2013 Category: Sleep Medicine Source Type: news

Nanosecond Dynamics of InfluenzaA/M2TM and an Amantadine Resistant Mutant Probed by Time-Dependent Red Shifts of a Native Tryptophan.
Abstract Proteins involved in functions such as electron transfer or ion transport must be capable of stabilizing transient charged species on time scales ranging from picoseconds to microseconds. We study the influenza A M2 proton channel, containing a tryptophan residue that serves as an essential part of the proton conduction pathway. We induce a transition dipole in tryptophan by photoexcitation, and then probe the dielectric stabilization of its excited state. The magnitude of the stabilization over this time regime was larger than that generally found for tryptophan in membrane or protein environments. M2 ac...
Source: Chemical Physics - August 30, 2013 Category: Chemistry Authors: Nanda V, Cristian L, Toptygin D, Brand L, Degrado WF Tags: Chem Phys Source Type: news

Amantadine ER Curbs Levodopa-Induced Dyskinesia in PDAmantadine ER Curbs Levodopa-Induced Dyskinesia in PD
An investigational extended-release formulation of amantadine with a unique chronotherapeutic pharmacokinetic profile eases levodopa-induced dyskinesia in a phase 2/3 study. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 25, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Influenza And Parkinson Drug Also Effective In Treating Pathological Gambling
Amantadine, a substance used for treating influenza and Parkinson, could be a new treatment option for pathological gambling according to researchers from Gabriele d'Annunzio University in Chieti, Italy, reporting at the 23rd Meeting of the European Neurological Society (ENS) in Barcelona. About 3,000 experts are gathering to discuss current developments in their field. The initial results seem quite promising although larger studies will be needed for confirmation. Amantadine is a non-specific glutamate blocker. According to pertinent studies, pathological gambling affects 0.2 to 5... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 11, 2013 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news

Combined use of electroconvulsive therapy and amantadine in adolescent catatonia precipitated by cyber-bullying - Goetz M, Kitzlerova E, Hrdlicka M, Dhossche D.
[Abstract unavailable] Language: Eng... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - April 28, 2013 Category: Global & Universal Tags: Age: Adolescents Source Type: news